FDA approvals in 2025: What changed and why it matters for ophthalmologists

A wave of 2025 FDA approvals across ophthalmology—spanning refractive, corneal, cataract, presbyopia, dry eye and retina—introduces platform integrations, less-invasive procedures and longer‑during therapies that could reshape treatment patterns and competitive dynamics. Key approvals include ZEISS’s MEL 90 excimer laser (integrated with VISUMAX 800/SMILE), Glaukos’ epithelium‑on cross‑linking Epioxa, BVI’s FineVision HP trifocal IOL, LENZ’s VIZZ (aceclidine 1.44%) for presbyopia, Alcon’s Tryptyr (acoltremon) for dry eye, Genentech’s broadened Susvimo indications (ranibizumab refillable implant), Neurotech’s ENCELTO (encapsulated cell therapy for macular telangiectasia type 2), Regeneron’s EYLEA HD (aflibercept 8 mg) and Celltrion’s EYDENZELT aflibercept biosimilar — trends that favor durability, lower treatment burden and pricing pressure from biosimilars, with likely modest-to-moderate effects on company revenues and market share as adoption scales.

Analysis

Market structure: Winners are small-to-mid ophthalmology innovators (GKOS for epithelium‑on cross‑linking, LENZ for VIZZ presbyopia drops, ALC for Tryptyr) plus platform players (ZEISS, Genentech/Susvimo) that shift care to higher-throughput or longer‑durability solutions. Losers include per‑injection anti‑VEGF incumbents (volume displacement from Susvimo and EYLEA HD + biosimilars) and any premium IOL vendor unable to differentiate; if Susvimo captures 15–25% of chronic bilateral patients, annual injection volumes could drop 20–40% in that cohort, pressuring per‑patient revenue. Cross‑asset: expect modest widening of small‑cap healthcare credit spreads (50–150bp potential for weaker operators), higher IV in ophthalmology equities near launches, and limited FX/commodity impact.

Risk assessment: Tail risks include payer noncoverage or restrictive CPT coding (high impact, low prob) and device/implant safety recalls that could cut peak adoption by >50%. Immediate risks (days) are headline-driven volatility; short term (30–90 days) hinge on CMS coverage/real‑world uptake signals; long term (6–24 months) depend on surgeon capital cycles and payer negotiations. Hidden dependencies: clinic capacity, training cadence, and reimbursement timing—real adoption often lags approvals by 6–12 months. Catalysts: Q2–Q4 2026 sales disclosures, Medicare coverage decisions within 30–120 days, and key KOL real‑world publications.

Key Decisions for Investors

• Establish a 2–3% long position in GKOS with a 6–12 month horizon to capture Epioxa uptake; implement a protective 15% stop loss and/or buy a 6–9 month 25–35% OTM call spread to cap downside and target +30–60% upside if install base and scripts accelerate in Q3–Q4 2026.
• Open a 2% position in LENZ via a 12–18 month LEAPS call spread (buy LEAPS, sell nearer‑dated calls) to play daily‑use VIZZ adoption; scale into position on any pullback >10% and take profits if retail/adoption data show >1% penetration of presbyopes in major ophthalmology networks within 12 months.
• Initiate a 1–2% tactical long in ALC on pullback (buy on >8% decline within 30 days) with covered call overlays (3–6 month) to generate income while waiting for Tryptyr reimbursement clarity; set an earnings/sales trigger to reassess at next quarterly report.
• Implement a pair trade: long LENZ (size 2%) vs short (size 1–1.5%) a high‑exposure anti‑VEGF incumbent if its IV remains elevated and no clear response to biosimilar pressure emerges; target spread capture of 10–25% over 6–12 months, with stop if the spread tightens by 50% of entry.
• Monitor three high‑probability catalysts in next 30–120 days—(1) CMS coverage decisions or local carrier drafts, (2) first real‑world uptake/installation counts from major surgical centers, (3) early prescription/adoption data—reassess allocations if adoption lags >50% vs management guidance or if payers issue restrictive coding.